Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Sep 16th, 9:31 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 26.81 - 29.20 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
The financial markets in 2025 have been a rollercoaster, culminating in a period of unprecedented euphoria. Both the S&P 500 and the Nasdaq Composite have surged to remarkable new all-time highs, largely driven by a pivotal shift in trade policy: the Trump administration's strategic pause in escalating tariff increases.
Via MarketMinute · September 16, 2025
Frankfurt, Germany – September 2025 – In a move largely anticipated by markets, the European Central Bank (ECB) opted in September 2025 to keep its key interest rates unchanged, maintaining a "steady hand" on monetary policy. This decision marks a significant divergence from the Federal Reserve (Fed) across the Atlantic, which is
Via MarketMinute · September 16, 2025
BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL, NXPLW) Launches Florida Sunshine Brand of Premium Vitamins and Supplements in Global Markets
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company, announced the official launch of its Florida Sunshine brand of premium vitamins and supplements across U.S., UK, and European markets, with expansion to China via Alibaba’s Tmall Global expected in Q4 2025. Supported by AI-powered digital advertising and dedicated e-commerce storefronts, the rollout targets rising global demand for preventive health and wellness products. The Made-in-USA liposomal formulations include vitamins C and D3, CoQ10, and Lutein, offering advanced absorption technology for immunity, heart health, and overall wellness. CEO David Phipps said the launch positions NextPlat to capture significant growth opportunities in the multibillion-dollar nutraceuticals market.
Via Investor Brand Network · September 16, 2025
New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease
UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages when the symptoms relied upon for the usual way to diagnose it haven’t shown up yet. Initial tests of this pen revealed an accuracy rate of 96.22%.
Via Investor Brand Network · September 16, 2025
BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches FAQ Page to Enhance Transparency and Investor Engagement
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the detection and treatment of breast cancer, has launched a new Frequently Asked Questions page on its corporate website at www.izocorp.com/faq . The resource provides accessible information on the company’s IzoView Breast CT Imaging System, development milestones, and competitive positioning, addressing topics such as breast density, imaging workflow, and comparisons with other modalities. Optimized for search and AI platforms, the FAQ page supports Izotropic’s investor relations, clinical outreach, and advocacy initiatives.
Via Investor Brand Network · September 16, 2025
Miami is a glamorous city that is also associated with energy and sophistication. It has been a haven of business executives, celebrities, and global travelers since its lively nightlife and its white sand beaches. To the people coming into Miami International Airport (MIA), the trip cannot just begin as you get into downtown. Rather, it […]
Via Worldnewswire · September 16, 2025
Northridge, CA () September 15, 2025 -- George’s Alignment & Brake Service is expanding its presence to better serve drivers in Northridge and surrounding neighborhoods.
Via Prodigy · September 15, 2025
April 2nd, 2025, will forever be etched in financial history as "Liberation Day," a moniker ironically assigned by the U.S. administration to the day sweeping new tariff policies were enacted. Instead, the global markets experienced a liberation of capital, as widespread panic selling triggered the largest worldwide decline since
Via MarketMinute · September 12, 2025
HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch
In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness plans for a technology that could transform how heart health is monitored both in clinical and home settings ( https://ibn.fm/dz7rY ).
Via Investor Brand Network · September 12, 2025
Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness
Researchers at University of Pittsburg have found that patients who consume sucralose regularly have a lower likelihood of benefiting from immunotherapy and having longer survival times. Sucralose is an artificial sweetener that is commonly used in a variety of diet products, such as Splenda. This research is the first to connect the dietary choices that people make to groundbreaking cancer treatments.
Via Investor Brand Network · September 12, 2025
Tesla's (NASDAQ: TSLA) audacious move to open its proprietary Supercharger network and connector, now formally known as the North American Charging Standard (NACS), has sent ripples through the automotive industry, effectively reshaping the future of electric vehicle (EV) charging infrastructure. This strategic repositioning is not merely a technical adjustment; it's
Via MarketMinute · September 11, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced it will host a key opinion leader event on Sept. 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu said the event will highlight safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives underscoring the compound’s potential role in addressing cancer drug resistance.
Via Investor Brand Network · September 11, 2025
Kennedy’s MAHA Plan to Make Kids Healthier Receives Mixed Reactions
On Tuesday, the U.S. federal administration published a report aimed at improving the health of children in the country. The report calls for wide-ranging policy changes and executive actions to tackle the chronic disease burden rising in the country. HHS Secretary Kennedy Jr. announced this report. However, reactions to the contents of the report have been mixed .
Via Investor Brand Network · September 11, 2025
BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the more accurate screening, diagnosis and treatment of breast cancers, announced its sponsored placement in a MarketScreener.com editorial titled From Healthcare to Automation: Investing In Next AI Wave . The article discusses the growing adoption of specialized AI applications across industries and features Izotropic’s IzoView technology as a rare early-stage medtech opportunity with the potential to establish a new standard of care in breast cancer imaging.
Via Investor Brand Network · September 11, 2025
Download Workshop Manuals, the premier online destination for professional automotive repair documentation since 2005, today announced a major expansion of its digital workshop manual library, adding comprehensive coverage for the latest 2024-2025 model year vehicles across all major automotive segments.
Via Get News · September 10, 2025
The MeatStick V Wireless Smart Meat Thermometer has been honored with the Red Dot Award: Product Design 2025 in the Kitchen Appliances category, one of the world’s most respected design competitions.
Via Get News · September 10, 2025
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
Via MarketMinute · September 10, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.
Via Investor Brand Network · September 10, 2025
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN’s BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company’s mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his outlook on the future of precision neuro-oncology.
Via Investor Brand Network · September 10, 2025
Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important.
Via Investor Brand Network · September 10, 2025
Tesla may still dominate the autonomous headlines, but Qualcomm’s partnership with BMW make it an interesting alternative for investors to consider.
Via MarketBeat · September 9, 2025
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025, according to a report by Noble Capital Markets Senior Vice President and Equity Research Analyst Robert LeBoyer. The company posted continued sales growth from two recently launched products, submitted an application for Hydronidone approval in China, and initiated a U.S. Phase 2 trial for the drug. Gyre also named Dr. Han Ying, a board member since January 2025, as CEO. Phase 3 data for Hydronidone in chronic hepatitis B-associated fibrosis met its primary endpoint of fibrosis regression, supporting an NMPA filing in 3Q25. With Breakthrough Therapy Designation, approval is anticipated in 2H26, followed by commercial launch in FY2027.
Via Investor Brand Network · September 9, 2025
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline ( https://ibn.fm/YGu4N ). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures for emerging infectious threats and bioterrorism risks. This combination sets the company apart as both a champion for underserved patient populations and a strategic partner in global public health preparedness.
Via Investor Brand Network · September 9, 2025
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week.
Via Investor Brand Network · September 9, 2025
Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference
The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents to prevent misuse, abuse and accidental exposure of drugs with high abuse potential, particularly opioids ( ibn.fm/1qrav ). With AVERSA(TM), Nutriband is aiming to transform traditional transdermal patches into safer tools for patients who require powerful pain relief, while simultaneously reducing the risks that have fueled a national epidemic.
Via Investor Brand Network · September 8, 2025